2,887
Participants
Start Date
June 30, 1998
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
Doxorubicine + docetaxel sequential
doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
doxorubicine + cyclophosphamide sequential
doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
doxorubicine + cyclophosphamide combined
doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
doxorubicine + docetaxel combined
doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Sanofi-Aventis, Macquarie Park
Sanofi-Aventis, Vienna
Sanofi-Aventis, Diegem
Sanofi-Aventis, Providencia Santiago
Sanofi-Aventis, Prague
Sanofi-Aventis, Hørsholm
Sanofi-Aventis, Berlin
Sanofi-Aventis, Budapest
Sanofi-Aventis, Dublin
Sanofi-Aventis, Netanya
Sanofi-Aventis, Milan
Sanofi-Aventis, Auckland
Sanofi-Aventis, Porto Salvo
Sanofi-Aventis, Bratislava
Sanofi-Aventis, Ljubljana
Sanofi-Aventis, Gauteng
Sanofi-Aventis, Barcelona
Sanofi-Aventis, Bromma
Sanofi-Aventis, Geneva
Sanofi-Aventis, Guildford Surrey
Sanofi-Aventis, São Paulo
Lead Sponsor
Sanofi
INDUSTRY